Modern Active Surveillance in Prostate Cancer: A Narrative Review
- Author(s)
- Pattenden, TA; Samaranayke, D; Morton, A; Ong, WL; Murphy, DG; Pritchard, E; Evans, S; Millar, J; Chalasani, V; Rashid, P; Winter, M; Vela, I; Pryor, D; Mark, S; Lawrentschuk, N; Thangasamy, IA;
- Details
- Publication Year 2023-02,Volume 21,Issue #1,Page 115-123
- Journal Title
- Clinical Genitourinary Cancer
- Publication Type
- Review
- Abstract
- The use of PSA screening has led to downstaging and downgrading of prostate cancer at diagnosis, increasing detection of indolent disease. Active surveillance aims to reduce over-treatment by delaying or avoiding radical treatment and its associated morbidity. However, there is not a consensus on the selection criteria and monitoring schedules that should be used. This article aims to summarize the evidence supporting the safety of active surveillance, the current selection criteria recommended and in use, the incidence of active surveillance, barriers existing to its uptake and future developments in patient selection.
- Publisher
- Elsevier
- Keywords
- Male; Humans; *Watchful Waiting; *Prostatic Neoplasms/diagnosis/therapy/epidemiology; Morbidity; Patient Selection; Prostate-Specific Antigen; Active surveillance; Intermediate risk prostate cancer; Low risk prostate cancer; Mri; Risk stratification
- Department(s)
- Surgical Oncology
- PubMed ID
- 36443163
- Publisher's Version
- https://doi.org/10.1016/j.clgc.2022.09.003
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-06-13 07:55:11
Last Modified: 2023-06-13 07:56:08